Abstract 2358
Background
Routine Electronic Monitoring of HRQoL (REMOQOL) in daily clinical care with real-time feedback to physicians could help to manage treatment-related toxicities, to personalize supportive care, and to assess the treatment benefit from the patients’ point of view. Physicians’ satisfaction with REMOQOL was evaluated in two French clinical trials (CT) assessing its feasibility.
Methods
Physicians’ satisfaction was evaluated in two CT: QOLIBRY a monocentric CT for breast, lung and colorectal cancers, and QUANARIE a multicentric CT involving 8 centres of France for renal cancer. Patients were invited to complete before each visit the EORTC QLQ-C30 questionnaire, cancer site-specific modules and selected items related to treatments, using the CHES software on tablets and/or computers at the hospital or at home. During the visit, the physicians had real-time access to visual summaries of HRQoL scores evolution. Physicians’ satisfaction was evaluated with a questionnaire specifically designed for these CT. The questionnaire addressed 43 items and aimed to evaluate if REMOQOL was a useful tool for the physician and the usability of the CHES software.
Results
Between September 2016 and March 2019, 45 physicians included 249 patients (QOLIBRY n = 193, QUANARIE n = 56). Twenty-six (58%) physicians completed the survey. Among them, 18 (69%) looked at the HRQoL results. HRQoL results helped to better understand the patient’s medical condition for 11 (61%) of the physicians. Discussion about HRQoL results with the patient was easy (n = 15; 83%) and REMOQOL improved communication with patients (n = 8; 44%). Physicians declared that REMOQOL helped them to adapt patient’s management (n = 10; 56%) and to support supportive care prescription (n = 8; 44%) without extending the time of consultations (n = 12; 67%). Seventy-three per cent (n = 19) would agree to integrate REMOQOL for all patients in their daily practice.
Conclusions
Physicians used REMOQOL as a complementary tool and were globally satisfied. However, information about the objectives, trainings and recommendations for using HRQoL results in routine are essentials and must be enhanced to involve all the physicians.
Clinical trial identification
QOLIBRY: NCT02844608 QUANARIE: NCT03062410.
Editorial acknowledgement
Legal entity responsible for the study
University Hospital of Besançon.
Funding
Novartis.
Disclosure
G. Mouillet: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self): Amgen; Honoraria (self): BMS; Honoraria (self): Roche; Honoraria (self), Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Travel / Accommodation / Expenses: Astellas. A. Thiery-Vuillemin: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Honoraria (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Honoraria (institution): Novartis; Honoraria (self), Honoraria (institution): Ipsen; Honoraria (self), Honoraria (institution), Travel / Accommodation / Expenses: Roche/Genentech; Honoraria (self), Honoraria (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Honoraria (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Honoraria (institution): Astellas Pharma. E. Curtit: Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Eisai; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer. G. Eberst: Honoraria (self): MSD; Honoraria (self): BMS; Honoraria (self): Boeringher Ingelheim; Honoraria (self): Roche; Honoraria (self): AstraZeneca. P. Barthelemy: Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Roche; Advisory / Consultancy: MSD; Advisory / Consultancy: Janssen; Advisory / Consultancy: Sanofi; Honoraria (self): Astellas. L. Geoffrois: Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: BMS. A. Anota: Honoraria (self), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self): BMS; Honoraria (self): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
4811 - Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population
Presenter: Baohui Han
Session: Poster Display session 1
Resources:
Abstract
2045 - The analysis of treatment sequences and clinical outcomes of thymic carcinoma
Presenter: Arakaki Motoko
Session: Poster Display session 1
Resources:
Abstract
4785 - Transcriptomic Difference of Thymoma and Thymic Carcinoma
Presenter: Naixin Liang
Session: Poster Display session 1
Resources:
Abstract
2864 - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Presenter: Seoyoung Lee
Session: Poster Display session 1
Resources:
Abstract
5015 - The study of tumor associated exosomes in crosstalk between esophageal carcinoma and lymphatic endothelial cells
Presenter: Weimin Mao
Session: Poster Display session 1
Resources:
Abstract
1339 - Up-regulation of IBSP expression predicts poor prognosis of Esophageal Squamous Cell Carcinoma patients
Presenter: Mingyue Wang
Session: Poster Display session 1
Resources:
Abstract
4083 - PD-L1 expression in primary tumour vs metastatic samples in the Phase 3 MYSTIC study in first-line metastatic (m) NSCLC
Presenter: Niels Reinmuth
Session: Poster Display session 1
Resources:
Abstract
5113 - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: post hoc analyses from the phase 3 JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
4256 - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): post hoc analyses from JAVELIN Solid Tumor
Presenter: Borys Hrinczenko
Session: Poster Display session 1
Resources:
Abstract
4305 - Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract